Global Selegiline Hydrochloride Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Selegiline Hydrochloride Market Research Report 2024
Selegiline Hydrochloride is the hydrochloride salt form of selegiline, a levorotatory acetylenic derivative of phenethylamine with antiparkinsonian effect. As a selective monoamine oxidase (MAO) inhibitor, selegiline has the greatest affinity for type B MAO, found mainly in the brain. Selegiline is converted by MAO B to an active moiety, which binds irreversibly at the active site of the enzyme's cofactor FAD (flavin adenine dinucleotide) molecule. This prevents the oxidative deamination of catecholamines and serotonin by MAO B, and leads to an increase in these neurotransmitters' activities resulting in improved motor function. In addition, this agent may inhibit re-uptake of dopamine by the neuron and prolong dopamine activity.
According to Mr Accuracy reports’s new survey, global Selegiline Hydrochloride market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Selegiline Hydrochloride market research.
Key manufacturers engaged in the Selegiline Hydrochloride industry include Somerset Pharmaceuticals Inc., Mylan Specialty, Draxis Health Inc., Deprenyl Research Ltd., Golden State Medical Supply, Mayne Pharma, Endo Pharmaceuticals, Par Pharmaceutical and Apotex Corp., etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Selegiline Hydrochloride were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Selegiline Hydrochloride market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Selegiline Hydrochloride market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Somerset Pharmaceuticals Inc.
Mylan Specialty
Draxis Health Inc.
Deprenyl Research Ltd.
Golden State Medical Supply
Mayne Pharma
Endo Pharmaceuticals
Par Pharmaceutical
Apotex Corp.
A-S Medication Solutions
Segment by Type
Tablet
Capsule
Parkinson's disease
Depression
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Selegiline Hydrochloride report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Selegiline Hydrochloride market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Selegiline Hydrochloride market research.
Key manufacturers engaged in the Selegiline Hydrochloride industry include Somerset Pharmaceuticals Inc., Mylan Specialty, Draxis Health Inc., Deprenyl Research Ltd., Golden State Medical Supply, Mayne Pharma, Endo Pharmaceuticals, Par Pharmaceutical and Apotex Corp., etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Selegiline Hydrochloride were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Selegiline Hydrochloride market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Selegiline Hydrochloride market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Somerset Pharmaceuticals Inc.
Mylan Specialty
Draxis Health Inc.
Deprenyl Research Ltd.
Golden State Medical Supply
Mayne Pharma
Endo Pharmaceuticals
Par Pharmaceutical
Apotex Corp.
A-S Medication Solutions
Segment by Type
Tablet
Capsule
Segment by Application
Parkinson's disease
Depression
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Selegiline Hydrochloride report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices